China SFDA Puts 307 Drugs On Digital List To Track Route To Market
This article was originally published in PharmAsia News
China's State FDA says it is placing 307 drugs considered essential on a national digital network by the end of the year so it can monitor them from production to market
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.